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A B S T R A C T
Purpose: Gabapentin and pregabalin are antiepileptic drugs (AEDs) with epilepsy and neuropathic pain
indications. The purpose of this study was to investigate pharmacokinetic variability of gabapentin and
pregabalin and indications for therapeutic drug monitoring (TDM) in clinical practice with focus on
gender aspects.
Method: Anonymous data from routine TDM-service at the National Center for Epilepsy regarding serum
concentration measurements of gabapentin and pregabalin, 2009–2013, were utilised. All included
samples were drug-fasting in the morning at steady-state.
Results: In total, 356 patients were included; gabapentin 189 (66% women), average age 53 years and
pregabalin 167 (56% women), average age 50 years. For gabapentin, mean serum concentration/dose(C/
D)-ratio was similar across genders. Only 13% of the patients had concentrations above the lower limit of
the reference range (70–120 mmol/L), which indicates a need for reevaluation of the reference range. For
pregabalin, the C/D-ratio in women (0.08  0.06) was 42% higher than in men (0.056  0.05; p < 0.05). The
pharmacokinetic variability (C/D-ratio) was >100-fold for both gabapentin and pregabalin. An indication of
use (epilepsy/pain/other) was stated in only 26% of the cases (n = 94). Epilepsy was assumed as indication
when other AEDs were also measured (50% of patients). This was similar for both genders and for both AEDs.
Indications for TDM were stated in 155 cases (44%) and were similar for gabapentin and pregabalin.
Conclusion: Gabapentin and pregabalin are more used in women than in men, and routine use of TDM is
most common in patients with epilepsy. Pharmacokinetic variability is extensive, highlighting a need for
individualisation of therapy regardless of indication.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Gabapentin and pregabalin are antiepileptic drugs (AEDs) with
epilepsy and neuropathic pain indications. Pregabalin is also
approved for generalised anxiety disorder. Previous population-
based studies in Norway have shown that these two AEDs only
have minor use in epilepsy and most extensive and still increasing
utilisation is in neuropathic pain [1,2]. Thus, many new patients* Corresponding author at: Institute of Pharmacy and Biomedical Science, Faculty
of Health Sciences, Oslo and Akershus University College of Applied Sciences,
Pilestredet 50, N-0167 Oslo, Norway. Tel.: +47 67236279.
E-mail address: cecilie.landmark@hioa.no (C. Johannessen Landmark).
http://dx.doi.org/10.1016/j.seizure.2015.02.017
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reare introduced to these AEDs. Implementation of therapeutic drug
monitoring (TDM) reveals pharmacokinetic variability in different
patient groups and needs further investigation in clinical practice,
regarding possible gender differences and age-related changes
[3,4]. The proposed reference ranges for gabapentin vary from
10 to 70 (lower limit) to 120 (upper limit) mmol/L, and for
pregabalin it is 10–30 mmol/L. The term ‘‘individual reference
concentrations’’ has been proposed for AEDs [3] because TDM is a
useful tool to individualise treatment, regardless of established
therapeutic range or whether the indication is epilepsy or
neuropathic pain.
The purpose of this study was to investigate pharmacokinetic
variability of gabapentin and pregabalin and indications for TDM
in clinical practice with focus on gender aspects.served.
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Anonymous data from routine TDM-service at the National
Center for Epilepsy regarding serum concentration measurements
of gabapentin and pregabalin, 2009–2013, were utilised.
The Norwegian Prescription Database (NorPD) [5] was used to
document the total number of patients with prescriptions of
gabapentin or pregabalin, gender and age (2009–2013).
2.1. Study material and analyses
The data regarding serum concentration measurements and
the use of AEDs were retrieved retrospectively from a TDM database,
including samples from the center and elsewhere in Norway (2009–
2013). The most recent measurement of AEDs was included for each
patient. The analyses were validated using routine liquid chro-
matographic methods at our department. All included samples were
drug-fasting in the morning at assumed steady-state concentra-
tions. All patients were anonymised, and data regarding gender, age,
use of AEDs, dose and serum concentration were collected. The study
was approved by the Regional Committee for Medical and Health
Research Ethics, Norway.
2.2. Calculations and statistics
The concentration/dose (C/D-ratio) relationships were calcu-
lated to demonstrate pharmacokinetic variability of the two drugs.Table 1
Characteristics of the patient population and comparison with the Norwegian Prescrip
Characteristics TDM data 
Gabapentin Pregabalin 
Gender (w/m) Total N = 189 Total N = 167 
66% w/34% m 56% w/44% m 
Age (years) Avg 53 years Avg 50 years 
Elderly 30 w (24%), 23 m (36%) Elderly 19 w (20
Doses (mg/day) 1744 mg  1029 w
1789 mg  1106 m
334 mg  117 w
387 mg  207 m
C/D-ratios
Gender 0.027  0.03 w, 0.029  0.03 m 0.08  0.06 w 0.0
Age, elderly vs
younger patients
0.044  0.055 vs 0.023  0.0027** 0.11  0.007 vs 0.
Enzyme-inducing
comedication vs
non-inducing/
monotherapy
N = 19, 0.018  0.008 vs N = 170,
0.029  0.003**
N = 21, 0.049  0.
0.075  0.007**
Indications
For TDM 
Routine 44 patients 43 patients
Adverse effects 13 13
Dose adjustment 9 9
Therapy failure 12 5
Acute intoxication 2 1
Misuse 2 0
Driving licence 1 0
Clinical indication 
Neuropathic pain 12 w/5 m 14 w/7 m
Epilepsy 13 w/9 m 9 w/11 m
Psychiatry 3 w/0 m 3 w/1 m
MS 2 w/1 m 0 w/1 m
Migraine 1 w/1 m 1 w/0 m
In total 47 patients
Other AEDS 46%
In total 47 patien
Other AEDS 56%
Enzyme-inducing comedication (carbamazepine, phenobarbital, phenytoin). C/D-ratio, 
* Statistically signiﬁcant changes, p < 0.05.
** Statistically signiﬁcant changes, p < 0.01.Patients 65 years were regarded as elderly. C/D-ratio is an inverse
proportional expression of clearance. Mean values and standard
deviations are presented. Enzyme-inducing comedication was
deﬁned as carbamazepine, phenobarbital and phenytoin, and
compared to non-inducing comedication/monotherapy [6].
Two-sided Students’ t-test with unequal variance was used
to calculate signiﬁcant differences between two groups
(p < 0.05).
3. Results and discussion
3.1. Patient characteristics
In total, 356 patients were included; gabapentin 189 (66%
women), average age 53 years and pregabalin 167 (56% women),
average age 50 years. There were 86 patients regarded as elderly
(65 years), which is 24% of the total population. The mean ages in
the TDM database tended to be lower than in the country as a
whole (Table 1). Gabapentin was used more than pregabalin in
Norway. For both drugs there were 59–60% women users in the
population as a whole, which is similar to the results from the TDM
database (56–66%, Table 1).
The pharmacokinetic variability (C/D-ratio) was >100-fold for
both gabapentin and pregabalin (Fig. 1a and b). Factors contribut-
ing to variability, age, gender and comedication are presented for
each drug.tion Database.
Norwegian Prescription
Database
Gabapentin Pregabalin
Average/year N = 26.265 Average/year N = 17.446
60% w/40% m 59% w/41% m
2008: 20 407 patients;
2013: 30 962 patients
2008: 17 117 patients;
2013: 19 638 patients
58.3 w, 56.5 m 58.1 w, 55.6 m
%), 14 m (19%)
NA NA
56  0.05 m* NA NA
063  0.006** NA NA
04 vs N = 146, NA NA
NA NA
NA NA
ts
concentration/dose ratio; NA, not applicable; w, women; m, men.
Fig. 1. (a) Dose and concentration relationship of (a) gabapentin (n = 189), ref. range
(70–120 mmol/L) and (b) pregabalin (n = 167), ref. range (10–30 mmol/L).
C. Johannessen Landmark et al. / Seizure 28 (2015) 88–91903.2. Gabapentin
For gabapentin the C/D-ratio was similar across genders. Elderly
patients had a 92% higher C/D-ratio, i.e. lower clearance as
compared to younger adults (Table 1), which may be explained by
gabapentin’s renal excretion that often is reduced with increasing
age [4]. We also found a 38% lower C/D-ratio, i.e. higher clearance
in combination with enzyme inducers, which was surprising, and
cannot be explained by the renal elimination pathway [7] (Table 1).
In a study of 41 children/young adults no effect of concomitant
enzyme inducers was reported [8]. Of the ﬁve patients with
concentrations above 120 mmol/L, there were two women and
three men.
A large number of patients (87%) had serum concentrations
below the lower limit of the proposed reference range (70 mmol/L),
which could result in unsatisfactory seizure control or pain relief.
Clinical data of effect and tolerability were, however, not accessible
from our database. This indicates a need to reevaluate the reference
range. There is a limited capacity of absorption of gabapentin and
large inter-/intra-patient variability in the absorption process. A
mean bioavailability of 49% was reported by Gidal et al. [9]. The
present results show many low concentrations and more frequent
use of TDM indicated by therapy failure in users of gabapentin than
in pregabalin, which may illustrate that many patients are not
optimally controlled. A dose of gabapentin does not correlate to
effect if it is not absorbed. Another explanation could be poor
adherence or non-continuous use.
Some laboratories use a lower limit of 10–20 mmol/L, whereas
our laboratory uses 70 mmol/L, based on early observations of
patients in clinical practice. In the present study, 35% of the
patients had concentrations below 20 mmol/L (Fig. 1a). A lower
limit may not be necessary, and may be misleading for theclinicians, as the patient may have a clinical effect even below the
reference range [3].
3.3. Pregabalin
For pregabalin the C/D-ratio in women was 42% higher than in
men (p < 0.05), although the mean doses were similar (Table 1).
The higher number of elderly women could partly explain
this ﬁnding due to lower elimination (80%). Another explanation
could be that higher doses than prescribed may have been taken.
There was also a similar decrease in C/D-ratio of 35% in
combination with enzyme inducers, similar to gabapentin
(Table 1). A previous study also demonstrated extensive variability
with pregabalin in 167 adult patients with epilepsy, a decreased
elimination in older patients and a similar effect with enzyme
inducers as we found [10].
The variability in serum concentrations was also extensive for
pregabalin, as 21% of the patients had serum concentrations below
the lower limit of 10 mmol/L and 18% had concentrations above the
upper limit of 30 mmol/L (Fig. 1b). Some patients tolerate
concentrations above the proposed range and even need it for
optimal clinical efﬁcacy. On the other hand, this also calls for
attention to the possibility of misuse, tolerance and dependence of
pregabalin, reported in international databases [11]. Of the
34 patients with concentrations above 30 mmol/L, there were
22 women. This ﬁnding calls for attention regarding a possibility of
use of higher doses than prescribed.
Reasons for the extensive variability in pharmacokinetics
presented include increased age and possible reduced renal
function, gender, and concomitant treatment with enzyme-inducing
AEDs.
3.4. Indications
Indications for TDM were stated in 155 cases (44%) and were
similar for gabapentin and pregabalin, except for more therapy
failure indications with gabapentin (Table 1).
A clinical indication was stated in only 26% of the cases
(epilepsy/pain/minor indications) (Table 1). Since serum concen-
trations of other AEDs were measured in about 50% of patients we
assume an epilepsy indication in many of these patients. The
results were similar between gender and AEDs. This means that
many of the few patients that use gabapentin or pregabalin for
epilepsy in Norway have implemented TDM, but few of the
patients treated for neuropathic pain.
The data from the NorPD demonstrated an increase in the
patient populations of gabapentin and pregabalin of 52% and 15%,
respectively (2009–2013). In Norway, gabapentin is the preferred
drug of the two for reimbursement of neuropathic pain treatment,
which may explain this ﬁnding.
3.5. Clinical implications
Patients treated for neuropathic pain often use other CNS-
active drugs (benzodiazepines/opioids), and thus pharmacody-
namic interactions are of importance. Pharmacokinetic inter-
actions are not a major concern due to renal excretion of both
drugs, but still we observed a more than 30% decrease in
C/D-ratios of both drugs with enzyme inducers. This may be of
clinical signiﬁcance in some patients. Gabapentin has variable
absorption, which is possibly revealed by low concentrations in
many of the cases. Many of the patients are elderly, and dosage
reductions may be necessary due to declining kidney function.
Gabapentin has level A evidence for use in the elderly with focal
epilepsies [12], although it does not seem to be frequently chosen
in clinical practice. High serum concentrations of pregabalin in
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regarding possible use of higher doses than prescribed.
In conclusion, the pharmacokinetic variability is extensive,
elucidating a need for individualisation of therapy and TDM. Age,
gender and enzyme inducers are contributing factors. The low
concentrations seen with gabapentin form the basis for reevalua-
tion of its reference range. Gabapentin and pregabalin are more
used in women than in men, with the most common practice of
applying TDM in patients with epilepsy. Regardless of indication,
TDM can be useful in acute and routine situations.
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